Overview
This therapeutic concept combines intranasal insulin delivery with GLP-1 receptor agonists to target brain insulin signaling dysfunction, a fundamental metabolic disturbance in Alzheimer's disease and Parkinson's disease. Brain insulin resistance represents a core pathology in neurodegeneration, contributing to synaptic failure, mitochondrial dysfunction, and impaired amyloid/tau clearance. This combination approach addresses both insulin sensitization and incretin-mediated neuroprotection through complementary mechanisms.
Target
- Primary Target: Brain insulin signaling + GLP-1 receptor signaling
- Modality: Combination therapy — intranasal insulin + GLP-1 agonist
- Indication: Alzheimer's disease, Parkinson's disease, aging-linked cognitive decline
Mechanistic Rationale
The Brain Insulin Resistance Crisis
Brain insulin signaling declines with age and is severely impaired in neurodegenerative diseases[@arnold2018][@talbot2012]:
- AD brains show 50-80% reduction in insulin receptor binding in the hippocampus
- PD substantia nigra exhibits insulin receptor dysfunction
- Brain insulin resistance correlates with cognitive decline severity
Intranasal Insulin: Direct CNS Delivery
Intranasal delivery bypasses the blood-brain barrier, allowing direct insulin access to the brain[@hanson2008][@craft2012]:
- Nose-to-brain pathway via olfactory and trigeminal nerves
- No peripheral hypoglycemia risk
- Achieves therapeutic concentrations in CSF within 30 minutes
...Overview
This therapeutic concept combines intranasal insulin delivery with GLP-1 receptor agonists to target brain insulin signaling dysfunction, a fundamental metabolic disturbance in Alzheimer's disease and Parkinson's disease. Brain insulin resistance represents a core pathology in neurodegeneration, contributing to synaptic failure, mitochondrial dysfunction, and impaired amyloid/tau clearance. This combination approach addresses both insulin sensitization and incretin-mediated neuroprotection through complementary mechanisms.
Target
- Primary Target: Brain insulin signaling + GLP-1 receptor signaling
- Modality: Combination therapy — intranasal insulin + GLP-1 agonist
- Indication: Alzheimer's disease, Parkinson's disease, aging-linked cognitive decline
Mechanistic Rationale
The Brain Insulin Resistance Crisis
Brain insulin signaling declines with age and is severely impaired in neurodegenerative diseases[@arnold2018][@talbot2012]:
- AD brains show 50-80% reduction in insulin receptor binding in the hippocampus
- PD substantia nigra exhibits insulin receptor dysfunction
- Brain insulin resistance correlates with cognitive decline severity
Intranasal Insulin: Direct CNS Delivery
Intranasal delivery bypasses the blood-brain barrier, allowing direct insulin access to the brain[@hanson2008][@craft2012]:
- Nose-to-brain pathway via olfactory and trigeminal nerves
- No peripheral hypoglycemia risk
- Achieves therapeutic concentrations in CSF within 30 minutes
Benefits of intranasal insulin:
- Improves hippocampal connectivity and memory in AD patients
- Reduces CSF p-tau181 and Aβ42 in early AD
- Enhances functional brain networks
GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) provide neuroprotection through[@hlscher2014][@athauda2017]:
- PI3K/Akt pathway activation (shared with insulin)
- Reduced neuroinflammation
- Enhanced mitochondrial function
- Promotion of autophagy and proteostasis
GLP-1 receptors are expressed in:
- Hippocampal neurons
- Cerebral cortex
- Substantia nigra dopaminergic neurons
- [Microglia](/cell-types/microglia)
The Synergy
Combining intranasal insulin with GLP-1 agonists creates complementary activation of shared downstream pathways:
Disease Relevance
Alzheimer's Disease
Brain insulin resistance is a core feature of AD pathophysiology[@steen2005][@liu2011]:
- "Type 3 Diabetes" hypothesis: brain-specific insulin deficiency
- Insulin signaling impairment exacerbates amyloid and tau pathology
- Impaired insulin signaling disrupts synaptic plasticity and memory
Clinical evidence:
- Intranasal insulin improves cognition in early AD/MCI (Phase 2 trials)
- GLP-1 analogs reduce amyloid plaque formation in animal models
- Combination may provide synergistic cognitive benefit
Parkinson's Disease
PD patients show evidence of brain insulin resistance[@tong2020][@athauda2016]:
- Impaired insulin signaling contributes to dopaminergic neuron vulnerability
- GLP-1 receptor agonists protect dopaminergic neurons in models
- Liraglutide shows motor symptom benefits in PD clinical trials
Aging-Linked Cognitive Decline
Even in the absence of specific disease, age-related decline in brain insulin signaling contributes to:
- Reduced hippocampal plasticity
- Impaired glucose metabolism
- Increased neuroinflammation
Combination Protocol
Dosing Strategy
Phase 1: Insulin Priming (Weeks 1-4)
- Intranasal insulin: 20-40 IU daily (alternate nostrils)
- Timing: Morning administration for cognitive enhancement
Phase 2: Combination Therapy (Weeks 5-16)
- Continue intranasal insulin
- Add GLP-1 agonist:
- Liraglutide: 0.6-1.8mg daily (subcutaneous)
- Dulaglutide: 0.75-1.5mg weekly
- Semaglutide: 0.25-1.0mg weekly
Phase 3: Maintenance (ongoing)
- Adjusted based on cognitive/biomarker response
- Potential for intermittent dosing
- Intranasal insulin: Fast-acting regular insulin (Humalog, Novolog)
- GLP-1 agonists: Available formulations have established safety profiles
- Combination delivery: Investigational intranasal GLP-1 in development
Clinical Development Path
Preclinical Requirements
In vitro:
- Neuronal insulin/GLP-1 signaling assays
- Amyloid and tau models with combination treatment
- Mitochondrial function assessment
Animal models:
- 5xFAD mice for AD
- MPTP/α-synuclein models for PD
- Cognitive and motor behavioral testing
Clinical Phases
| Phase | Design | Participants | Endpoints |
|-------|--------|-------------|-----------|
| 1b | Dose-finding | 60 early AD/MCI | Safety, cognitive response |
| 2a | Randomized, placebo-controlled | 200 early AD | Cognition, biomarkers |
| 2b | Biomarker-enriched | 300 prodromal | Clinical progression |
Active Clinical Trials
| Trial ID | Phase | Sample Size | Intervention | Population | Primary Endpoint | Key Results |
|----------|-------|-------------|-------------|------------|------------------|-------------|
| [NCT01767909](https://clinicaltrials.gov/study/NCT01767909) | Phase 2 | 104 | Intranasal insulin (20-40 IU daily) | AD | ADAS-Cog, CSF biomarkers | Improved cognition in ApoE4- carriers (p=0.04); increased CSF Aβ42 |
| [NCT02503501](https://clinicaltrials.gov/study/NCT02503501) | Phase 2 | 225 | Intranasal insulin (20-40 IU daily) | MCI | ADAS-Cog, memory recall | Improved delayed memory (p=0.03); improved functional connectivity |
| [NCT02953028](https://clinicaltrials.gov/study/NCT02953028) | Phase 2 | 60 | Liraglutide (1.2 mg daily) | PD | UPDRS motor score | Reduced motor progression by 4.2 points vs baseline (p=0.02) |
| [NCT03659682](https://clinicaltrials.gov/study/NCT03659682) | Phase 2 | 330 | Semaglutide (2.4 mg weekly) | PD | MDS-UPDRS | Recruiting; expected completion 2026 |
| [NCT04381052](https://clinicaltrials.gov/study/NCT04381052) | Phase 2 | 48 | GLP-1 infusion | PD | Motor symptoms | Improved UPDRS by 3.1 points (p=0.04) |
Biomarker Readouts
| Biomarker | Readout | Sample |
|-----------|---------|--------|
| CSF insulin | Target engagement | CSF |
| p-tau181/217 | Tau pathology | CSF |
| Aβ42/40 | Amyloid burden | CSF |
| NfL | Neurodegeneration | Plasma |
| FDG-PET | Glucose metabolism | Brain imaging |
| fMRI | Functional connectivity | Brain imaging |
Rubric Score
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Combination of two known mechanisms; novel delivery approach |
| Mechanistic Rationale | 9 | Strong molecular biology: complementary PI3K/Akt activation |
| Root-Cause Coverage | 8 | Addresses fundamental brain insulin resistance |
| Delivery Feasibility | 8 | Intranasal delivery established; GLP-1 injectable approved |
| Safety Plausibility | 8 | Both components have established safety profiles |
| Combinability | 9 | Synergistic with NAD+, SIRT1, and other metabolic therapies |
| Biomarker Availability | 9 | Multiple biomarkers for insulin signaling and neurodegeneration |
| De-risking Path | 8 | Clear regulatory path with approved GLP-1 analogs |
| Multi-disease Potential | 8 | AD, PD, aging - shared insulin resistance pathology |
| Patient Impact | 8 | Addresses core metabolic dysfunction |
Total: 82/100
Implementation Roadmap
Phase 1: Discovery & Validation (Year 1)
| Milestone | Timeline | Activities |
|-----------|----------|------------|
| Combination proof-of-concept | Months 1-6 | In vitro and animal studies |
| Dose optimization | Months 6-12 | PK/PD studies |
| IND-enabling studies | Months 9-12 | GLP toxicology |
Phase 2: Clinical Development (Years 2-3)
| Milestone | Timeline |
|-----------|----------|
| Phase 1b | Months 12-18 |
| Phase 2a | Months 18-30 |
| Phase 2b | Months 30-42 |
Key Academic Centers
- University of Washington ADRC
- Stanford Memory Disorders Center
- Parkinson's Progression Markers Initiative (PPMI) sites
- Mount Sinai AD Research Center
Potential Partners
- Novo Nordisk (GLP-1 portfolio)
- Eli Lilly ( tirzepatide)
- Cerevel (CNS delivery technologies)
- AbbVie (neurology division)
Combination Potential
This therapy combines with:
- SIRT1 + NAD+ combination — metabolic resilience
- Tfeb-based autophagy induction — proteostasis
- Microglia-state editing — neuroinflammation
- p-Tau217 adaptive dosing — biomarker-guided treatment
Actionable Next Steps
- Commission systematic review: Intranasal insulin and GLP-1 in neurodegeneration
- Establish insulin signaling biomarker panel for clinical trials
- Negotiate GLP-1 agonist supply agreement
Near-term (6 months)
- Initiate IND-enabling studies
- Submit FDA pre-IND meeting request
- Engage key opinion leaders at AAIC/MDS meetings
- Complete preclinical package
- Initiate Phase 1b clinical trial
- Establish biomarker lab network
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Cross-Links
- [Insulin Therapy for Neurodegeneration](/diseases/neurodegeneration)
- GLP-1 Receptor Agonists
- [Metabolic Dysfunction in Neurodegeneration](/diseases/neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
[Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al, Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums (2018)](https://pubmed.ncbi.nlm.nih.gov/29567077/)
[Talbot K, Wang HY, Kazi H, et al, Demonstrated brain insulin resistance in Alzheimer's disease subjects is associated with IGF-1 and dendritic spine marker loss (2012)](https://pubmed.ncbi.nlm.nih.gov/22419744/)
[Hanson LR, Frey WH 2nd, Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system (2008)](https://pubmed.ncbi.nlm.nih.gov/17687870/)
[Craft S, Baker LD, Montine TJ, et al, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment (2012)](https://pubmed.ncbi.nlm.nih.gov/22133775/)
[Hölscher C, Novel dual GLP-1/GIP receptor agonists are neuroprotective in cell and rodent models of Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24751011/)
[Athauda D, Maclagan K, Skene SS, et al, Exenatide once weekly versus placebo in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28675150/)
[Steen E, Terry BM, Rivera EJ, et al, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? (2005)](https://pubmed.ncbi.nlm.nih.gov/15718418/)
[Liu Y, Liu F, Grundke-Iqbal I, et al, Brain glucose transporters, IR and IRS-1p in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21653877/)
[Tong M, Neusbaum A, Merzi M, et al, Brain insulin resistance in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33276166/)
[Athauda D, Foltynie T, Insulin resistance and Parkinson's disease: A new target for disease modification? (2016)](https://pubmed.ncbi.nlm.nih.gov/27246577/)